Zejula, Revatio Advisory Committee Meetings Cancelled; Palovarotene Panel Postponed

 
• By Brenda Sandburg

Panel to review overall survival data on GSK’s Zejula for ovarian cancer ‘is no longer needed,’ US FDA says. Meeting to consider pediatric indication for Viatris’ Revatio was also cancelled though sNDA remains active. FDA to review new information on Ipsen’s palovarotene clinical trial data.

Cancelled meeting
FDA cancels two advisory committee meetings, including 22 November consideration of Zejula sNDA, and postpones another • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers